Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;42(1):1-11.
doi: 10.4143/crt.2010.42.1.1. Epub 2010 Mar 31.

Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges

Richard Choo  1
Affiliations

Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges

Richard Choo. Cancer Res Treat. 2010 Mar.

Abstract

A progressively rising level of serum prostate specific antigen (PSA) after radical prostatectomy (RP) invariably indicates the recurrence of prostate cancer. The optimal management of patients with post-RP PSA relapse has remained uncertain due to a wide variability in the natural course of post-RP PSA relapse and the inability to separate a recurrent disease confined to the prostate bed from that with occult distant metastasis. Management uncertainty is further compounded by the lack of phase III clinical studies demonstrating which therapeutic approach, if any, would prolong life with no significant morbidity. Radiotherapy has been the main therapeutic modality with a curative potential for patients with post-RP PSA relapse. This review article depicts issues and challenges in the management of patients with post-RP PSA relapse, presents the literature data for the efficacy of salvage radiotherapy, either alone or in combination of androgen ablation therapy, and discusses future directions that can optimize treatment strategies.

Keywords: PSA relapse; Post radical prostatectomy; Salvage radiotherapy.

PubMed Disclaimer

References

    1. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393–1401. - PubMed
    1. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–S19. - PMC - PubMed
    1. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766–772. - PubMed
    1. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994;152:1358–1368. - PubMed
    1. Presti JC, Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998;52:1079–1084. - PubMed